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Abstract
Background: Nitric oxide (NO) has long been recognized to affect muscle contraction [1], both through activation of
guanylyl cyclase and through modification of cysteines in proteins to yield S-nitrosothiols. While NO affects the contractile
apparatus directly, the identities of the target myofibrillar proteins remain unknown. Here we report that nitrogen oxides
directly regulate striated muscle myosins.
Principal Findings: Exposure of skeletal and cardiac myosins to physiological concentrations of nitrogen oxides, including
the endogenous nitrosothiol S-nitroso-L-cysteine, reduced the velocity of actin filaments over myosin in a dose-dependent
and oxygen-dependent manner, caused a doubling of force as measured in a laser trap transducer, and caused S-
nitrosylation of cysteines in the myosin heavy chain. These biomechanical effects were not observed in response to S-
nitroso-D-cysteine, demonstrating specificity for the naturally occurring isomer. Both myosin heavy chain isoforms in rats
and cardiac myosin heavy chain from human were S-nitrosylated in vivo.
Significance: These data show that nitrosylation signaling acts as a molecular ‘‘gear shift’’ for myosin—an altogether novel
mechanism by which striated muscle and cellular biomechanics may be regulated.
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Introduction
Products of nitric oxide (NO) synthase activation have long been
recognized to affect muscle contraction [1]. Contraction and
contractility are thought to be regulated indirectly through
activation of guanylyl cyclase to generate cGMP, and by direct
action of NO on proteins. Protein sulfhydryl modification by
oxidized NO to yield S-nitrosothiol (S-NO) moieties is widely
accepted as an important regulatory mechanism. The breadth and
importance of the protein targets, however, remains to be fully
understood.
Skinned (membrane-permeablized) muscle preparations re-
spond to NO donors with reduced Ca
2+ sensitivity [2–4], ATPase
activity [2,3], and velocity of shortening [3]. In intact cardiac
fibers NO causes a decrease in calcium sensitivity and an increase
in rigor force [5]. These data suggest a direct effect of NO on
myofibrillar proteins in muscles that is independent of calcium
handling and cGMP-mediated phosphorylation. Unfortunately, it
is difficult to determine in these preparations which of the
myofibrillar proteins are being affected and how. It was reported
in a 1998 abstract that NO donors completely inhibit myosin
function as measured in vitro (J.L. Tan, M. Heidecker, J.D. Cohen,
M.B. Fowler & J.A. Spudich, 1998). In recent work, Nogueira and
coworkers found that the ATPase activity of skeletal myosin can be
reversibly inhibited by nitroso-S-glutathione but not by donors of
NO [6]. These studies together suggest that myosin is a target for
regulation by endogenous donors of NO.
To gain a better understanding of whether and in what manner
the physiological function of myosin is affected by NO, we tested
the effects of a NO donor (DEA NONOate) and small,
endogenous nitrosothiols (nitroso-cysteine) on the force and
velocity generated by skeletal and a-cardiac myosins in vitro.W e
found that DEA NONOate reduced actin filament velocity over
striated myosins, but increase isometric force generated by myosin.
While nitroso-L-cysteine had a similar effect to NONOates,
nitroso-D-cysteine had no functional effect on myosin, showing
stereospecificity for the endogenous NO donor. Our data show a
strong yet nuanced effect of NOS products on striated muscle
myosins that extends beyond mere inhibition, suggesting that
myosin is indeed directly regulated by NO.
Results
NO slows motility by striated myosins and HMM
Using the in vitro motility assay we observed the movement of
single fluorescently labeled actin filaments gliding over a myosin-
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protocol that avoids the use of reducing agents that would otherwise
reverse S-nitrosylation [9]. Briefly, myosin or heavy meromyosin
(HMM) was bound to a nitrocellulose-coated coverslip in a flow cell
and flushed with a reducing agent-free buffer. HMM is a proteolytic
subfragment of myosin that includes the paired heads of myosin, the
associated light chains, and the short coiled-coil region called S2,
but lacks the tail that allows myosin to form thick filaments. DEA
NONOate was diluted into buffer pre-equilibrated to either 15 or
152 mmHg PO2 and added immediately to the flow cell for 1
minute. Actin filament motion was observed by epifluorescence
microscopy after removing the donor.
We found a dose-dependent response of both cardiac and
skeletal muscle myosin function to DEA NONOate (Figure 1A
and B), though cardiac myosin was more sensitive than skeletal.
There was no difference in the response of full-length skeletal
myosin and skeletal HMM to donor, indicating that the responsive
domain of myosin is in subfragments 1 or 2 (Figure 1C). These
effects were reversible by exposure to 10 mM DTT, and could not
be duplicated using sulpho NONOate, which is less likely than
DEA NONOate to transfer NO
+ to thiols.
S-nitrosylation by NO radical itself requires an electron
acceptor and therefore can be oxygen-dependent. We therefore
measured dose-response curves at three oxygen concentrations –
0, 15 (physiological), and 152 (atmospheric) mmHg PO2. Cardiac
myosin was approximately 10X more sensitive to donor than was
skeletal when measured in terms of the concentration to achieve a
significant reduction in velocity. Inhibition of motility in cardiac
myosin did not differ significantly at physiological and atmospheric
PO2 (Figure 1A, p=0.25). The Ki for reduction of actin filament
velocity propelled by cardiac myosin was 6606250 nM donor, or
approximately 66 nM [NO] at 152 mmHg PO2. In contrast there
was a trend toward blunting of the skeletal muscle myosin dose
response at high PO2 (Figure 1B); the Ki for inhibition was 3240
and 138 nM [NO] at 152 and 15 mmHg PO2, respectively
(p=0.03).This suggests that at physiologic oxygen concentrations
the response of myosin to nitrogen oxides is already maximized. In
the absence of oxygen, 1 mM DEA NONOate had no effect on
motility. These data show that myosin function is responsive to
NO in an oxygen- and isoform-dependent manner.
Myosin generates more force in the presence of NO
As a physiologically-relevant measure of the force production in
the purified actomyosin system, an optical trap assay was used to
measure the stall force of multiple myosin molecules interacting
with an actin filament [10]. Laser trapped beads were bound to
the trailing ends of motile actin filaments (Figure 2A) to measure
the force at which forward motion stalled. Repeated over a range
of actin filament lengths, these measurements can be used to
estimate the time-averaged isometric force generated by myosin.
Figure 1. Dose-response and PO2 interactions of the NO donor
DEA NONOate on myosin. A: Cardiac myosin at high (open symbols,
20%, 152 mmHg) and physiologic (solid symbols, 2%, 15 mmHg) PO2.
PO2 has no significant effect on the response of isolated cardiac myosin
to the NONOate. B: Same as A, but with skeletal muscle myosin which
was significantly more sensitive to NO at lower PO2.* p ,0.05 compared
to no DEA NONOate at 15 mmHg. ** p,0.05 compared to no DEA
NONOate at 152 mmHg. C: There is no difference in the dose-response
curves of full length skeletal myosin (gray) and HMM (black), indicating
that the site of NO action lies within the head or S2 regions of myosin.
N=3. The [NO] scale bar shows the approximate NO concentration for
the equivalent DEA NONOate concentration given our exposure times
and conditions.
doi:10.1371/journal.pone.0011209.g001
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100 mM for 1 minute. Both 10 and 100 mM caused force
generation by myosin to nearly double - 1.960.2 and 1.860.2
fold over control as indicated by the slopes of the force/heads/
filament relationship (Figure 2B). To confirm these results, we
performed ‘‘mixture’’ experiments to measure the relative force
generated by nitrosylated myosins. Analogous to a tug-of-war,
donor-treated and untreated myosins are laid down in a motility
assay over a range of relative concentrations, ranging from 100%
treated and 0% untreated, to 0% treated and 100% untreated.
The relationship between filament velocity and fractional
composition can be used as a measure of relative force production
by the two myosin populations [11]. At any given mixture,
velocities of actin filament velocities were closer to those of NO
+ -
treated myosin than to control myosin (Figure 2C). Interpreted
according to Harris et al. [11], the data yield a relative production
of 2.160.3 higher force by DEA NONOate-treated cardiac
myosin compared to untreated myosin (p=0.003). These data too
suggest that NO (as NO
+) exposure approximately doubles the
time-averaged force generated by skeletal and cardiac myosins.
Myosin is stereoselective for an endogenous NO donor
An effect of exogenous nitrogen oxide on myosin function does
not necessarily imply regulation. We therefore used the naturally
occurring donor nitrosocysteine (SNO-cys) - a nitrosothiol in cells
that may be important in signaling. Its D- and L-isomers have
similar chemistries and rates of decay to yield NO
+, so any
preference in the response to the naturally occurring L-isomer
Figure 2. Measurement of time-averaged isometric force after exposure to NO. A: A streptavidin-coated bead is held in a laser trap and
touched to the trailing (+) end of a moving, biotinylated, TRITC-phalloidin labeled actin filament. Displacement of the bead from trap center was
followed using back focal plane interferometry [34,35]. B: Force versus number of potentially bound, force-generating heads (a reflection of filament
length) for three conditions, control (N, black lines), 10 mM DEA NONOate (#, red lines) and 100 mM DEA NONOate (., green lines). Steeper slopes
indicate proportionately higher forces per head. Solid lines indicate the regression fit, while the dashed lines show 95% confidence intervals. Each
data point is an independent force measurement (N=25, 20 and 10 for 0, 10, and 100 mM DEA NONOate respectively). C: Mixtures experiment for rat
cardiac myosin. The line shows the fit of equation 1 from Harris et al. [11] yielding a relative force production 2.1-fold higher after DEA NONOate-
treated compared to control. N=3.
doi:10.1371/journal.pone.0011209.g002
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regulation via trans-nitrosylation – the transfer of NO
+ from a
nitrosothiol to a thiol. To test for functional stereospecificity to an
endogenous donor, skeletal and cardiac myosins were exposed for
1 minute in the dark to SNO-L-cys and SNO-D-cys. We found
that SNO-D-cys had no effect on myosin-based motility
(Figure 3A). In contrast, SNO-L-cys reduced actin filament
velocities by approximately one half at 5 mM. Motility was
restored to near control levels by two 2-minute exposures to
ultraviolet light (Figure 3B) which breaks S-NO bonds [12] with
buffer washes after each exposure to remove the freed NO. Stereo-
selectivity for the naturally occurring isomer of a small ligand is
generally considered strong evidence for specificity, and hence
regulation.
The effects of SNO-cysteine and other nitrogen oxides on
myosin are unlike those of alkylating agents (e.g. N-ethylmalei-
mide), which completely inhibit myosin cycling and lead to the
formation of strong, rigor-like bonds with actin.
Myosin heavy and light chains are nitrosylated in vitro
and in vivo
We next tested whether the L- or D-isomers of SNO-cysteine
could nitrosylate myosin. Skeletal muscle HMM was exposed at a
1:2 molar ratio with each isomer (12 mM) and the incorporated
NO measured by chemiluminesence. We found that SNO-L-cys
lead to the incorporation of 1.16 NO-equivalents/myosin heavy
chain, while SNO-D-cys lead to the incorporation of only 0.25.
These data suggest that myosin is more efficiently nitrosylated by
the L- than by the D-isomer of S-NO-cys. Liberation of NO by
SNO-D-cys during removal by microdialysis may explain the
small level of stereoselectivity; the nitrosylation state at the earliest
time points after SNO-cys exposure remains to be determined.
Nonetheless, nitrosylation of myosin is stereo-selective and while
reversible, persists over time.
To determine which chains of the myosin heterohexamer were
stereospecifically nitrosylated, we used a coumarin switch assay
[13], similar to the standard biotin switch assay [14] to identify
nitrosylated proteins in a mixture. In this variation, AMCA
fluorophore rather than biotin replaced all NO moieties so that
nitrosylated proteins could be rapidly imaged under UV light and
subsequently stained with colloidal coomassie to determine the mass
for each protein band. Normalizing the nitrosylation signal to total
protein is critical for quantifying nitrosylation in myosin heavy
chain, or for any other protein where (a) sample-to-sample protein
recovery after the biotin switch is not uniform, or (b) the number of
modified cysteines is low relative to the mass of the protein. Both are
the case for myosin heavy chain and failure to normalize against the
mass of protein in each individual electrophoretic band (as opposed
to an overall protein assay) will mask a small number of consistently
nitrosylated cysteines in the large protein.
All three isoforms of myosin heavy chain and most of their
associated myosin light chains were readily nitrosylated by SNO-
L-cys (Figure 4A) – these included the slow and fast isoforms of the
essential light chains, and the skeletal regulatory light chain. The
only light chain that was not significantly nitrosylated by SNO-L-
cys was the cardiac myosin regulatory light chain. The myosin
heavy chain was significantly stereoselective for nitrosylation by
the L- over the D-isoforms of SNO-cys as assayed by coumarin
switch. The L/D nitrosylation per unit mass was 1.960.1 and
3.860.9 for skeletal and cardiac myosin heavy chains, respectively
(p,0.001 for a ratio .1.0). Once again, the low degree of
stereoselectivity was probably related to the extended times
necessary to remove the protein from donor using precipitating
agents. We found no significant selectivity by any of the light
chains for nitrosylation by L- over D- SNO-cys (L/D nitrosylation
per unit mass ,1). This suggests that the functional stereoselec-
tivity we observed (Figure 3) is the result of heavy chain
nitrosylation, and not light chain nitrosylation.
We also measured the endogenous level of nitrosylation in rat
skeletal and cardiac myosins, and human cardiac myosin. High-
Figure 3. Stereo-selective effects of SNO-L-cysteine on myosin.
A: Dose-response showing that SNO-L-cysteine, the naturally occurring
isomer, has pronounced effects on actin filament velocity, while SNO-D-
cys does not. B: Effects of 5 mM L- and D-isomers of SNO-cys on actin
filament velocities over skeletal (dark bars) and cardiac (light bars)
myosin, and recovery by exposure to ultraviolet light – strong support
of nitrosylation as the underlying modification. *Different from control
(p,0.05). **Different from SNO-L-cys alone (p,0.05). N=5.
doi:10.1371/journal.pone.0011209.g003
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(endogenous), treated with ascorbate (control), or treated with
10 mM SNO-L-cys (L) and subjected to the coumarin switch assay
followed by coomassie staining and protein mass normalization as
described earlier. Relative endogenous nitrosylation was calculated
after mass normalization as (endogenous - control)/(L - control).
We found that rat skeletal and cardiac myosin heavy chains were
nitrosylated in vivo to 50% and 30%, respectively, of the level
induced using 10 mM SNO-L-cys. Human cardiac myosin heavy
chain was nitrosylated to a level of approximately 20% (Figure 4B).
These are minimum estimates, since there will be some
spontaneous loss of NO equivalents during protein extraction.
We were not able to make comparable measurements of light
chain nitrosylation since the high ionic strength extracts had an
abundance of low molecular weight proteins that could lead to
misidentification of the light chain bands.
Discussion
Ourdata suggestthat either nitrosylation or trans-nitrosylation act
as a ‘‘gear shift’’ for myosin, switching it on-the-fly from a relatively
high-speed, low-force motor to a low-speed, high-force motor at
physiologicalconcentrationsof NO. The question naturallyarises, to
what purpose? Regulation of contraction under physiological and
pathological conditions by NO is complex, involving direct and
cGMP-dependent pathways [15], so a simple answer is unlikely to
suffice. It has been proposed that the direct effect of NO in muscle
cells is to slow contraction and its associated metabolism [16]. One
possible example of this is exercise, during which NO increases in
skeletal muscle [17]. NO or S-nitrosothiols may thus serve both to
increase oxygen supply to the tissue through vascular dilation and
simultaneouslyshift contractile function to higherforce generation at
the expense of lowered shortening velocity.
The concentrations of S-nitrosothiols used in these experiments
are thought to span the physiological range. Free [NO] on the order
of 100 nM to several mM has been measured adjacent to stimulated
cardiac myocytes [18–21]. However, the presence of these levels of
free radical in the presence of ,200 mM concentrations of
myoglobin in the myoplasm seems unlikely [22]. It is entirely
possible that the concentrations of nitrosothiols in myocytes and
other cells are ,100 nM [23,24]. However, as with any reversible
bimolecular reaction, it is not only the concentration of reactants
but the forward and reverse reaction rate constants for the
nitrosylation reaction that will ultimately determine the functional
impact of NO production. The forward reaction we know from
motility experiments occurs in seconds. We also know that the
effects of NO donors persist for at least several minutes once donor
is removed, presumably due to slow spontaneous reversal of the S-
NO modification. Thus S-NO-myofibrillar proteins may accumu-
late in cells, even in the presence of myoglobin.
The pattern of effects on force and actin filament velocity
suggests a model where S-NO modification of muscle myosin
alters the attached time and duty cycle of myosin. From the
perspective of a single molecule, the velocity of actin over a pure
myosin is related to the inverse of its attached lifetime (ton) – how
long during each hydrolytic cycle myosin remains attached to
actin. In contrast, the time-averaged force generated by myosin is
related to its duty cycle (ton/(ton+toff)) – the fraction of the total
cycle time myosin is attached to actin. Thus a doubling of ton with
no change in the detached time (toff) would result in a 50%
decrease in actin filament velocity, and an approximate 2X
increase in average force. Striated muscle myosins are thought to
have low duty cycles; thus doubling ton could produce the observed
changes in force and velocity without large changes in total cycle
time as measured by ATPase rates. This may explain why
Nogueira and coworkers [6] found no effect of DEA NONOate on
ATPase rates; in addition, in those particular experiments their
readout of myosin function was a non-functional, ion-activated
ATPase assay rather than a functional actin-activated assay.
One might speculate that nitrosylation is a general regulatory
mechanism for myosin-based motility. There are a number of
cysteines that are well conserved across myosin isoforms, including
two especially reactive cysteines [25] (cys707 and cys697) among
the nine in the motor domain of the heavy chain. Interestingly, the
reactive cysteines themselves and the encompassing alpha helix are
highly conserved in muscle myosins, even across species. However,
conservation of the reactive cysteines does not fully extend to non-
muscle myosins. Myosin V, for example, possesses one of the two
reactive cysteines and conserves much of the encompassing helix
from muscle myosins while other myosins have neither reactive
cysteine. If one or both reactive cysteines are indeed the point of
NO regulation of muscle myosin, then one would predict that
myosins lacking these cysteines would be unresponsive to NO and
nitrosothiols. It is possible, however, that non-muscle myosins
incorporate different sites for regulation by NO, including one
proposed in myosin heavy chain 9 [26], that better meet their
particular regulatory needs. Further, we found that some of the
light chains of striated myosins can be nitrosylated in vitro. There
are obviously several possible sites for regulation of myosins by NO
and its endogenous donors. Determining which of these is
responsible for the effects observed here will be the subject of
future studies, as will the identification of other potential NO
regulatory sites in the contractile apparatus of cells.
Methods
Ethics Statement
Use of human myocardium was approved by the University of
Virginia Human Investigation Committee, Protocol 10274 to Drs
Figure 4. Myosin nitrosylated in vivo and in vitro. A: Rat skeletal
and cardiac myosin heavy (MHC) and light chains were nitrosylated by
in vitro exposure to SNO-L-cysteine (L) over the control level (C). The
ventricular/slow skeletal isoform of the essential light chain (ELC) could
be nitrosylated, as could the regulatory light chain (RLC) and fast
essential light chain of skeletal muscle myosin. The regulatory light
chain of cardiac myosin was not significantly nitrosylated. B: Myosin
heavy chain was endogenously (E) nitrosylated in rat skeletal and
cardiac muscle, and also in human myocardium (MHC AMCA). A protein
staining of the same gel is shown (MHC total) to illustrate how
nitrosylation is normalized against protein mass to reveal low levels of
nitrosylation between zero (A, ascorbate-treated) and maximum (L,
SNO-L-cys-treated). See the text for details of the normalization
procedure. Without normalization, variations in recovery between
protein bands (as shown, typical) will mask single (or a few) nitrosylated
cysteines in large proteins like myosin. N=3 in all cases.
doi:10.1371/journal.pone.0011209.g004
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specimens) that have been collected solely for non-research
purposes (such as medical treatment and/or diagnosis).’’ Rat
myocardial and skeletal muscle tissues were obtained from the
cadavers of animals sacrificed under other investigators’ IACUC
protocols; no animals were sacrificed specifically for this study, and
it was therefore deemed exempt from IACUC approval.
Proteins
Myosin was prepared from rat skeletal and cardiac tissues by the
method of Shiverick [27] and actin according to Pardee and
Spudich [28]. Skeletal HMM was prepared from fresh myosin
according to Margossian and Lowey [29]. Actin was biotinylated
as described previously [10].
In vitro motility assays and donor treatments
Exposures to NO donors take place in reducing agent-free
solutions bubbled with N2/O2 to obtain the desired oxygen
tension. NONOates (DEA and sulpho) were obtained commer-
cially (Alexis/Cayman) and stored frozen in 100 mM KOH. Stock
NONOates were diluted in 10 mM KOH ,30 seconds before use.
Treatment buffers were formulated such that the pH of the
reaction mixture changes by less than 0.1 units upon addition of
donor. L- and D-S-NO-cys were prepared as 10 mM stock
solutions and were stored as aliquot at 280uC. Stock SNO-cys was
diluted to working concentrations in actin buffer ,30 seconds
before use.
The DTT-free motility assay is described elsewhere [9]. Briefly,
aliquots of all solutions were vacuum degassed on ice for 20
minutes. Preparations were performed in a darkened room to
prevent donor photolysis. Myosin or HMM was applied to a flow
cell consisting of a nitrocellulose-coated coverslip and glass slide to
a final concentration of 200 mg/ml and 80 mg/ml, respectively.
The flow cell was washed with degassed ‘‘actin buffer’’ (25 mM
KCl, 25 mM Imidazole, 1 mM EGTA, 4 mM MgCl2, pH 7.4)
after a one minute incubation. Donor was applied to the flow cell
in actin buffer equilibrated with 0%, 2%, or 20% oxygen (balance
nitrogen). After a one minute incubation with donor, the flow cell
was washed with degassed low salt buffer and blocked with 0.5%
(v/v) Tween 20 in degassed low salt buffer for myosin, or 2%
PVP40 in degassed low salt buffer for HMM for 1 min. TRITC-
phalloidin labeled actin filaments were introduced, followed by
two degassed actin buffer washes. A low salt motility buffer
(25 mM KCl, 25 mM Imidazole, 1 mM EGTA, 4 mM MgCl2,
1 mM ATP, 0.5% methylcellulose, pH 7.4) was added and actin
filament movement was recorded. The motility buffer also
contained an oxygen scavenger system described in Guo and
Guilford [30].
Actin filaments were tracked used a energy-minimalization
segmentation routine, previously described [9]. At least 50 actin
filaments were tracked for each experimental trial, though
typically hundreds were used, and each condition repeated a
minimum of three times. The sample number (N) was conserva-
tively taken as the number of independent experiments, not the
number of filaments tracked. Filament velocities were normalized
to daily controls.
Laser trap force assay
As a physiologically-relevant measure of the force production in
the purified actomyosin system, an optical trap assay was used to
measure the stall force of multiple myosin molecules interacting
with an actin filament [10]. Briefly, 0.97 mm streptavidin-coated
microspheres (Bangs Laboratories) were fluorescently labeled with
TRITC-labeled BSA. HMM was applied to flow cells and
subsequently blocked with 1 mg/ml BSA. TRITC-phalloidin
labeled and biotinylated actin filaments were added. Finally,
streptavidin microspheres were resuspended in actin buffer with
100 mM ATP and introduced to the flow cell to initiate motility.
Individual fluorescent beads were trapped and a motile actin
filament was chosen. A trapped bead was brought into contact
with the trailing (+) end of the motile filament and held until the
forward motion of the filament stalled. Stall force measurements
were repeated over a range of actin filaments lengths (1–7 mm).
The number of HMM heads that may interact with each actin
filament was estimated from HMM density measurements [30].
Mixture Assay
Force generation by donor treated myosin relative to untreated
myosin was measured using a mixture assay [31,32] with
modifications. Myosin was exposed in solution to DEA NONOate
or nitrosocysteine in buffer bubbled with 2% or 20% oxygen and
allowed to sit for 35 minutes on ice. Treated and untreated myosin
were mixed in ratios of 100:0, 75:25, 50:50, 25:75 and 0:100
immediately before application to a flow cell. Motility was then
performed as described above. An alternative approach was also
used, namely introducing 50% diluted myosin to the flow cell,
treating with donor for one minute (as above), and subsequently
introducing a second bolus of 50% diluted myosin. The two
methods gave comparable results.
Mixture assay data were analyzed by the model of Harris et al.
[11] assuming a compression factor of 0.26. The model was fit to
the data using SigmaPlot to find the force of the fast myosin
relative to the slow.
Nitrosothiol quantitation
S-nitrosothiols were measured in 6 mM skeletal HMM after
treatment with 12 mM L- or D-SNO-cysteine, and with or without
HgCl2 pretreatment to break the S-nitrosothiol bond (negative
control). Samples were dialyzed for 1.5 hours to remove excess
SNO-cysteine. Assays are carried out under He in a purge vessel
containing 1 mM cysteine and 100 mM CuCl, pH 7.0, 50uC
connected to an NOA chemiluminescence detector (Sievers NOA
280, Boulder, CO) with added carbon monoxide (CO) to the inert
gas flow through the reflux chamber, preventing NO autocapture
by heme groups. Metal carbonyls (<0.7 ppm in research grade
CO) must be removed, as both Ni- and Fe-carbonyls chemilumi-
nescence in the presence of O3. Therefore, the CO source gas is
passed through iodine crystals and activated charcoal, blended
with the He stream in a gas proportioner. Oxidized cys was
replaced, and residual Hb removed, by refreshing the reflux
chamber after each sample injection [33]. Water and nitrite NO2
2
solution were injected as additional negative controls before each
experiment.
Coumarin switch assay
S-nitrosylation was measured using a modification [13] of
Jaffrey’s biotin switch assay [14]. AMCA-HPDP was used rather
than biotin-HPDP during labeling to allow S-nitrosylated proteins
to be imaged in-gel prior to staining total protein; this aids in
normalization of fluorescence against protein mass in each band.
Between treatments, protein was precipitated using either 10%
trichloroacetic acid (TCA) at room temperature for 10 minutes, or
90% cold acetone (220uC) for 20 minutes followed by 10 minutes
of centrifugation, depending on whether the myosin heavy chain
or myosin light chains, respectively, were desired; myosin heavy
chain does not precipitate constitutively in acetone, and myosin
light chains do not precipitate constitutively in TCA.
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EDTA, neocuproine, as in [14]) were exposed to SNO-cys. After
precipitation to remove donor, reduced cysteines were blocked
with 1% methyl methanethiosulfonate (MMTS) in HENS (HEN
with 2% SDS) at 50uC for 30 minutes. Protein was precipitated
twice to remove MMTS, and resuspended in 1 mM AMCA-
HPDP in HENS with 4 mM sodium ascorbate. Labeling was at
room temperature in the dark for 1 hour. Protein was precipitated
to remove excess label, and resolved on 6% (for myosin heavy
chain) or 12% gels (for myosin light chains). ACMA-labeled
protein was imaged in an Alpha Innotech gel documentation
system using a 460 nm filter and an excitation wavelength of
365nm. Gels were subsequently stained with colloidal coomassie
and imaged in brightfield for total protein. The identity of the
ventricular/slow skeletal isoform of the essential light chain band
was confirmed using Western blot against MYL3.
Statistics
Statistical comparison of means was by z-test. The slopes of
fitted lines, such as those from the laser trap assay, were compared
as described in Rao and coworkers [10]. N unless otherwise stated
is the number of independent experimental preparations, not the
number of individual samples.
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